Literature DB >> 7574537

Antiviral effect in human cytomegalovirus-infected cells, pharmacokinetics, and intravitreal toxicology in rabbits of acyclovir diphosphate dimyristoylglycerol.

S Shakiba1, W R Freeman, M Flores-Aguilar, D Munguia, M Tatebayashi, G Besen, R Amani, C A Wiley, C Vuong, K A Aldern.   

Abstract

Acyclovir diphosphate dimyristoylglycerol (ACVDP-DG) is a lipid prodrug which is active against ACV-resistant strains of herpes simplex virus because of its intracellular metabolism to ACV monophosphate. In human cytomegalovirus (HCMV)-infected MRC-5 cells, ACVDP-DG was ninefold more active than ACV. When liposomal [8-3H]ACVDP-DG was injected intravitreally at the maximum nontoxic dose of 1 mumol in rabbits, the drug remained above its estimated 90% HCMV-inhibitory concentration for 18 days. Intravitreal ganciclovir persists above its 90% inhibitory concentration for only 1 to 2 days. ACVDP-DG may be useful as a local treatment for HCMV retinitis.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7574537      PMCID： PMC162748          DOI： 10.1128/AAC.39.6.1383

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Ocular toxicity of multiple intravitreal DHPG injections.

Authors:  M O Yoshizumi; D Lee; V Vinci; S Fajardo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

2.  Transscleral iontophoresis of foscarnet.

Authors:  D Sarraf; R A Equi; G N Holland; M O Yoshizumi; D A Lee
Journal:  Am J Ophthalmol       Date:  1993-06-15       Impact factor: 5.258

3.  Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine.

Authors:  D R Dolnak; D Munguia; C A Wiley; E De Clercq; G L Bergeron-Lynn; C Boscher; J D Connor; C Sherwood; E Capparelli; R Armani
Journal:  Invest Ophthalmol Vis Sci       Date:  1992-04       Impact factor: 4.799

4.  Intraocular 9-([2-hydroxy-1-(hydroxymethyl) ethoxy] methyl) guanine levels after intravitreal and subconjunctival administration.

Authors:  J Schulman; G A Peyman; M B Horton; J Liu; R Fiscella; J Pulido; J C Barber; P de Miranda
Journal:  Ophthalmic Surg       Date:  1986-07

Review 5.  Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.

Authors:  D Faulds; R C Heel
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

6.  Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome.

Authors:  M Díaz-Llopis; E Chipont; S Sanchez; E España; A Navea; J L Menezo
Journal:  Am J Ophthalmol       Date:  1992-12-15       Impact factor: 5.258

7.  Reversible inhibition of cytomegalovirus replication by phosphonoformate.

Authors:  B Wahren; B Oberg
Journal:  Intervirology       Date:  1980       Impact factor: 1.763

8.  Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.

Authors:  B D Kuppermann; M Flores-Aguilar; J I Quiceno; L S Rickman; W R Freeman
Journal:  Arch Ophthalmol       Date:  1993-10

9.  Acyclovir diphosphate dimyristoylglycerol: a phospholipid prodrug with activity against acyclovir-resistant herpes simplex virus.

Authors:  K Y Hostetler; S Parker; C N Sridhar; M J Martin; J L Li; L M Stuhmiller; G M van Wijk; H van den Bosch; M F Gardner; K A Aldern
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

10.  Acquired immune deficiency syndrome. Ocular manifestations.

Authors:  G N Holland; J S Pepose; T H Pettit; M S Gottlieb; R D Yee; R Y Foos
Journal:  Ophthalmology       Date:  1983-08       Impact factor: 12.079
View more
  1 in total

Review 1.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.